ATTENUATION OF HYPOCRETIN/OREXIN SIGNALING IS ASSOCIATED WITH INCREASED MORTALITY RISK AFTER MYOCARDIAL INFARCTION
Tématický okruh: Sekundární prevence | |
| Typ: Ústní sdělení - lékařské , Číslo v programu: 389 | |
Etický kodex: Konzultant: ServierPřednášková činnost: Servier Podpora výzkumu / granty: Supported by Ministry of Health of the Czech Republic, grant nr. NV 19-09-00125 and by the project National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, Project No. LX22NPO5104) - Funded by the European Union - Next Generation EU. | |
| Wohlfahrt P. 1, Melenovský V. 2, Jarolím P. 3, Kotrč M. 2, Jenča D. 2, Dlouhá D. 2, Šramko M. 2, Kotrč M. 2, Mrázková J. 2, Piťha J. 2, Adámková V. 4, Kautzner J. 2 1 Pracoviště preventivní kardiologie, IKEM, Praha, 2 Klinika kardiologie, IKEM, Praha, 3 Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States, 4 Pracoviště preventivní kardiologie, IKEM | |
Aims Hypocretin/orexin system has been shown to play a role in heart failure. Whether it also influences myocardial infarction (MI) outcomes is unknown. We evaluated the effect of rs7767652 minor allele T associated with decreased transcription of the hypocretin/orexin receptor-2 and circulating Orexin A concentrations on mortality risk after MI. | |